title: [Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)].
abstract: Neuroendocrine tumors (neuroendocrine tumors-NET) are a heterogeneous group of neoplasms with a common embryological origin and diverse biological behavior, derived from cells of the neuroendocrine system, the system APUD (amine precursor uptake and decarboxylation). They are characterized by overexpression of all five somatostatin receptors (SSTR1-SSTR5), particularly type 2 (SST2). Surgical resection of the tumor is the treatment option, with a possibility of complete remission in patients with limited disease. Somatostatin analogs (octreotide and lanreotide) are the treatment of choice in patients with residual disease, particularly when it comes to NET non-pancreatic origin. Systemic chemotherapy is administered primarily to patients with poorly differentiated carcinomas. PRRT treatment is recommended in case of non-responsiveness of the disease. The ideal candidates for PRRT are patients with unresectable disease of high and intermediate differentiation. Somatostatine analogs radiolabelled with Indium-111 ((111)In), Yttrium-90 ((90)Y), Lutetium-177 ((177)Lu) and Bismuth-213 ((213)Bi), are selectively concentrated in the tumor cells, causing maximum tissue damage to tumors and with fewer effects on healthy tissue and the immune system. In the current review, it was demonstrated that patients with unresectable grade 1 or 2 disease showed increased PFS (progression free survival) and OS (overall survival), while quality of life was improved after PRRT treatment as compared to somatostatin analogs, chemotherapy and other targeted therapies.
authors.affiliation: 1st Laboratory of Radiology of Athens University, Aretaieion Hospital, Athens, Greece. hpavlidou@gmail.com.
authors.forename: Dimitris G
authors.initials: DG
authors.lastname: Papamichail
authors.forename: Paraskevi E
authors.initials: PE
authors.lastname: Exadaktylou
authors.forename: Vasiliki D
authors.initials: VD
authors.lastname: Chatzipavlidou
mesh_terms: D019317:Evidence-Based Medicine; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods / Q000706:statistics & numerical data; D018358:Neuroendocrine Tumors / Q000378:metabolism* / Q000401:mortality / Q000532:radiotherapy*; D010456:Peptides, Cyclic / Q000493:pharmacokinetics; D015995:Prevalence; D011868:Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000378:metabolism*; D012307:Risk Factors; D013004:Somatostatin / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D010456:Peptides, Cyclic; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin